Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.

Attached hereto as Exhibit 99.1 is a copy of the Interpace Diagnostics Group, Inc. (the “Company”) press release dated September 20, 2017 related to written notice received from the Listing Qualifications department of The NASDAQ Capital Market. The information furnished in this Item 7.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.

Item 8.01. Other Events

On September 18, 2017, the Company received written notice (the “Letter”) from the Listing Qualifications department (the “Staff”) of The NASDAQ Capital Market notifying the Company that the Staff has determined that since the Company has appointed Dr. Felice Schnoll-Sussman to its Board of Directors and audit committee, it has regained compliance with Listing Rule 5605(c)(2). The Letter also stated that the matter related to Listing Rule 5605(c)(2), previously disclosed by the Company in its Current Report on Form 8-K filed October 13, 2016, has been closed.

The foregoing description is qualified in its entirety by reference to the full text of the Letter, which is filed as an exhibit to this Current Report on Form 8-K and incorporated herein by reference in its entirety.

Item 9.01. Financial Statements and Exhibits

Interpace Diagnostics Group, Inc. Exhibit
EX-99.1 2 ex99-1.htm   Interpace Diagnostics Announces Receipt of Letter From Nasdaq Confirming Compliance With Audit Committee Requirements   Parsippany,…
To view the full exhibit click here

About Interpace Diagnostics Group, Inc. (NASDAQ:IDXG)

Interpace Diagnostics Group, Inc., formerly PDI, Inc., is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. The Company operates through molecular diagnostics segment. It offers molecular tests, such as PancraGen, which is a pancreatic cyst molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy, and ThyraMIR, which assesses thyroid nodules risk of malignancy utilizing a gene expression assay. Through its molecular diagnostics business, the Company provides diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are focused on early detection of cancer.